bimatoprost

Bimatoprost is a synthetic prostamide and structural analog of prostaglandin F2α used primarily to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It achieves this by increasing the outflow of aqueous humor through both the trabecular meshwork and uveoscleral pathways, thereby lowering intraocular pressure. Unlike other prostaglandin analogs, bimatoprost does not act on known prostaglandin receptors but is thought to mimic endogenous prostamides; its precise mechanism remains unclear as no specific receptor has been identified. Bimatoprost is also indicated for the treatment of eyelash hypotrichosis (insufficient eyelashes), where it promotes longer, thicker, and darker eyelash growth. The drug was initially approved in 2001 for ocular hypertension and later for eyelash hypotrichosis in 2008[1][2][3][4][5]. Developed by Allergan, bimatoprost is available in various dosage forms including solution, implant, and topical formulations.

Brand names

DurystaLatisseLumigan

Other names

Bimatoprost implantBimatoprost sustained-release implant